Rocket VR Health and MGH Initiate Clinical Trial


Next-generation immersive mental health technology leverages virtual reality

Rocket VR Health (RVH), a virtual reality digital therapeutics company addressing mental health treatments, has initiated a randomized control trial with Massachusetts General Hospital (MGH), Harvard Medical School's largest teaching hospital. The 80-patient trial is examining the feasibility and preliminary efficacy of RVH's virtual reality digital therapeutic in improving quality of life, symptom burden, psychological distress and self-efficacy in adult patients with blood cancers admitted for hematopoietic stem cell transplantation (HCT) at MGH. Patients undergoing HCT treatment experience immense physical and psychological symptoms during a prolonged four-week hospitalization and endure significant short-term and long-term distress that affects their quality of life and their physical and psychological well-being.

Interactive therapeutic content, such as high-definition doctor holograms and meditations taking place at nature-based locations, is delivered on standalone Pico Neo 3 headsets that use a Qualcomm XR2 processor for next-generation performance and have over 2.5 hours of battery life. The headsets weigh only 1.3 pounds and have an ergonomic design while leveraging gaze-based controls removing the need for physical controllers.

Reference: Rocket VR Health and Massachusetts General Hospital Announce Initiation of Randomized Control Trial Investigating Efficacy of Virtual Reality Digital Therapeutic. BOSTON, March 7, 2023 /PRNewswire.

© 2024 MJH Life Sciences

All rights reserved.